EMPHASIS-HF Mortality Reduction Index

EMPHASIS-HF Mortality Reduction Index: Explanation and Clinical Context The EMPHASIS-HF Mortality Reduction Index is designed to estimate the potential benefit of eplerenone in reducing all-cause mortality among patients with mild to moderate symptomatic heart failure with reduced ejection fraction (HFrEF), as studied in the EMPHASIS-HF trial. The EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) trial demonstrated that the addition of eplerenone—a selective aldosterone receptor antagonist—to standard therapy (ACE inhibitors, beta-blockers, and loop diuretics) significantly reduced the risk of death and hospitalization for heart failure in patients with NYHA class II–III and left ventricular ejection fraction ≤35%. In the original study, eplerenone reduced the composite endpoint of cardiovascular death or heart failure hospitalization by 37% (hazard ratio 0.63, 95% CI 0.54–0.74; p<0.001).

The estimated absolute risk reduction for all-cause mortality over 2 years was approximately 4–5%, corresponding to an NNT of about 22–25 patients to prevent one death. This calculator provides an approximate estimation of mortality reduction benefit by incorporating clinical parameters (age, NYHA class, LVEF, renal function, serum potassium, and comorbidities) that influence the baseline mortality risk profile. The resulting prediction may assist clinicians in therapeutic decision-making and patient counseling regarding the magnitude of eplerenone’s prognostic benefit.